Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Epidermodysplasia verruciformis: Langerhans cells, immunologic effect of retinoid treatment and cytogenetics

Summary

A case study is presented of a 44-year-old negroid male with epidermodysplasia verruciformis (EV), cutaneous carcinomas, and impaired cell-mediated immunity (CMI), infected with human papillomavirus type 8 and 17. Analysis was made of (a) T6+and HLA-DR+Langerhans cells (LCs) by immunoperoxidase staining in lesional and clinically normal skin before and during retinoid treatment, (b) the effect of retinoid treatment on CMI in vivo and in vitro, and (c) cytogenetic aspects related to chromosomal instability. The results showed the virtual absence of T6+and HLA-DR+LCs in koilocytic areas of epidermis involved with EV. Light-exposed, clinically normal skin also demonstrated microscopic EV lesions largely devoid of T6+and HLA-DR+LCs. Retinoid treatment with etretinate (Ro 10-9359) appeared both to increase the CMI response in vitro to T-cell mitogens and to influence the in situ pattern of T6+and HLA-DR+LCs. The cytogenetic study did not show evidence of spontaneous or UV-induced chromosomal instability.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Androphy EJ, Dvoretzky I, Maluish AE, Wallace HJ, Lowy DR (1984) Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha-interferon. J Am Acad Dermatol 11:197–202

  2. 2.

    Androphy EJ, Dvoretzky I, Lowy DR (1985) X-linked inheritance of epidermodysplasia verruciformis. Arch Dermatol 121:864–868

  3. 3.

    Bagot M, Heslan M, Dubertret L, Roujeau JC, Touraine R, Levy JP (1985) Antigen-presenting properties of human epidermal cells compared with peripheral blood monnonuclear cells. Br J Dermatol 113 [Suppl 28]:55–60

  4. 4.

    Bauer R, Orfanos CE (1985) Effects of synthetic retinoids on human peripheral blood lymphocytes and polymorphonuclears in vitro. In: Cunliffe WJ, Miller AJ (eds) Retinoid therapy. MTP Press, Lancaster, pp 101–118

  5. 5.

    Bleumink E, Nater JP, Schraffordt Koops H, The TH (1974) A standard method for DNCB sensitization testing in patients with neoplasms. Cancer 33:911–915

  6. 6.

    Blitstein-Willinger E, Haas N, Nurnberger F, Stuttgen G (1986) Immunological findings during treatment of multiple keratoacanthoma with etretinate. Br J Dermatol 114:109–116

  7. 7.

    Chardonnet Y, Viac J, Thivolet J (1986) Langerhans cells in human warts. Br J Dermatol 115:669–675

  8. 8.

    Claudy AL, Touraine JL, Mitanne D (1982) Epidermodysplasia verruciformis induced by a new human papillomavirus (HPV-8). Arch Dermatol Res 274:213–219

  9. 9.

    Craifemberghi S, Gavazzoni R, Coglio G, Pozzo G (1982) Epidermodisplasia verruciforme di Lewandowsky-Lutz. Giorn It Derm Venereol 117:191–194

  10. 10.

    Faure M, Dezutter-Dambuyant C, Schmitt D, Gaucherand M, Thivolet J (1985) Langerhans cell induced cytotoxic T-cell responses against normal human epidermal cell targets: in vitro studies. Br J Cermatol 113 [Suppl 28]:114–117

  11. 11.

    Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP (1985) Latent papillomavirus and recurrent genital warts. N Engl J Med 313:784–788

  12. 12.

    Gassenmaier A, Lammel M, Pfister H (1984) Molecular cloning and characterization of the DNAs of human papillomaviruses 19, 20 and 25 from a patient with epidermodysplasia verruciformis. J Virol 52:1019–1023

  13. 13.

    Giessen M van der, Postma S, The TH (1985) Isolation of highly purified lymphocyte subsets for functional studies by means of an indirect rosette technique. Scand J Immunol 22:41–49

  14. 14.

    Guilhou JJ, Malbos S, Barneon S, Habib A, Baldet P, Meynadier J (1980) Epidermodysplasie verruciforme. Etude immunologique. Ann Dermatol Venerol 107:611–619

  15. 15.

    Haftek M, Jablonska S, Orth G (1985) Specific cell-mediated immunity in patients with epidermodysplasia verruciformis and plane warts. Dermatologica 170:213–220

  16. 16.

    Herberman RB (1984) Possible role of natural killer cells and other effector cells in immune surveillance against cancer. J Invest Dermatol 83:137s-140s

  17. 17.

    Jablonska S, Orth G, Lutzner MA (1982) Immunopathology of human papillomavirus-induced tumors in different tissues. Springer Semin Immunopathol 5:33–62

  18. 18.

    Jacyk WK, Lechner W (1984) Epidermodysplasia verruciformis in lepromatous leprosy. Dermatologica 168:202–205

  19. 19.

    Jacyk WK, Subbuswamy SG (1979) Epidermodysplasia verruciformis in Nigerians. Dermatologica 159:256–265

  20. 20.

    Jong MCJM de, Blanken R, Nanninga J, Voorst Vader PC van, Poppema S (1986) Defined in situ enumeration of T6 and HLA-DR expressing epidermal Langerhans cells: morphologic and methodologic aspects. J Invest Dermatol 87:698–702

  21. 21.

    Kallenberg CGM, Voort-Beelen JM van der, Amaro J de, The TH (1981) Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol 43:478–485

  22. 22.

    Kaminski M, Pawinska M, Jablonska S, Szmurlo A, Majewski S, Orth G (1985) Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol 121:84–86

  23. 23.

    Kanerva LO, Johansson E, Niemi KM, Lauharanta J, Salo OP (1985) Epidermodysplasia verruciformis. Clinical and light- and electron-microscopic observations during etretinate therapy. Arch Dermatol Res 278:153–160

  24. 24.

    Kienzler JL, Laurent R, Coppey J, Favre M, Orth G, Coupez L, Agache P (1979) Epidermodysplasie verruciforme. Ann Dermatol Venereol 106:549–563

  25. 25.

    Kraemer KH (1983) Heritable diseases with increased sensitivity to cellular injury. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds) Update: dermatology in general medicine. McGraw-Hill, New York, pp 113–140

  26. 26.

    Kremsdorf D, Favre M, Jablonska S, Obalek S, Rueda LA, Lutzner MA, Blanchet-Bardon C, Voorst Vader PC van, Orth G (1984) Molecular cloning and characterization of the genomes of nine newly recognized human papillomavirus types associated with epidermodysplasia verruciformis. J Virol 52:1013–1018

  27. 27.

    Lutzner MA, Blanchet-Bardon C, Orth G (1984) Clinical observations, virologic studies and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 83:18s-25s

  28. 28.

    Pfister H, Nurnberger F, Gissmann L, Hausen H zur (1981) Characterization of a human papillomavirus from epidermodysplasia verruciformis lesions of a patient from Upper-Volta. Int J Cancer 27:645–650

  29. 29.

    Proniewska M, Jablonska S (1980) UV-induced DNA repair synthesis in patients with epidermodysplasia verruciformis. Dermatologica 160:289–296

  30. 30.

    Scheres JMJC (1972) Identification of two Robertsonian translocations with a Giemsa banding technique. Hum Genet 15:253–256

  31. 31.

    Smeets DFCM, Scheres JMIC, Hustinx TWJ (1984) The fragile site on chromosome 3. Hum Genet 67:351

  32. 32.

    Steinberg BM, Topp WC, Schnieder PS, Abramson AL (1983) Laryngeal papillomavirus infection during clinical remission. N Engl J Med 308:1261–1264

  33. 33.

    Sutherland GR, Hecht F (1985) Fragile sites on human chromosomes. Oxford University Press, New York

  34. 34.

    Tanigaki T, Kanda R, Yutsudo M, Hakura A (1986) Human papillomavirus DNA detected in squamous-cell carcinoma tissue of a patient with epidermodysplasia verruciformis. Arch Dermatol Res 279:66–67

  35. 35.

    Verweij H, Voorst Vader PC van, Houthoff HJ, Gips CH (1985) Quantitative analysis of retinoids in human serum and tissue samples using high performance liquid chromatography. In: Saurat JH (ed) Retinoids: new trends in research and therapy. Karger, Basel, pp 301–304

  36. 36.

    Voorst Vader PC van, Jaspers NGJ, Kamp AWM van der (1984) Retinoic acid and defective UV light induced DNA excision repair in xeroderma pigmentosum: absence of ameliorating effect. Arch Dermatol Res 276:201–202

  37. 37.

    Voorst Vader PC van, Orth G, Dutronquay V, Driessen LHHM, Eggink HF, Kallenberg CGM, The TH (1986) Epidermodysplasia verruciformis: skin carcinoma containing human papillomavirus type 5 DNA sequences and primary hepatocellular carcinoma associated with chronic hepatitis B virus infection in a patient. Acta Derm Venereol 66:231–236

  38. 38.

    Wojtulewicz-Kurkus J, Glinski W, Jablonska S, Podobinska I, Obalek S (1985) Identification of HLA antigens in familial and non-familial epidermodysplasia verruciformis. Dermatologica 170:53–58

Download references

Author information

Correspondence to P. C. van Voorst Vader.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van Voorst Vader, P.C., de Jong, M.C.J.M., Blanken, R. et al. Epidermodysplasia verruciformis: Langerhans cells, immunologic effect of retinoid treatment and cytogenetics. Arch Dermatol Res 279, 366–373 (1987). https://doi.org/10.1007/BF00412621

Download citation

Key words

  • Epidermodysplasia verruciformis
  • Cell-mediated immunity
  • Langerhans cells
  • Retinoid treatment
  • Cytogenetics